RxDoctor Payments Data

Robert Edelman, MD

Ophthalmology · Bradenton, FLNPI 1790783553

Payments from drug & device makers

$2,047in general payments, 2019–2025

Across 32 payments — averaging $63.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$1K
  • Alcon$418
  • AbbVie$203
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$106
  • Bausch & Lomb Americas Inc.$93
  • Glaukos Corporation$76
  • plus $67 from 2 others

What the payments were for

  • Consulting fees$1,08553%
  • Food & beverage$96247%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,047 in reported general payments places this provider in the 50th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida

Medicare billing

Part B allowed, 2024
$562,099
Medicare patients
1,563
Services billed
6,402

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost432$275,575
RestasisCyclosporine124$137,781
Alphagan PBrimonidine Tartrate281$129,519
RhopressaNetarsudil Mesylate164$91,556
CombiganBrimonidine Tartrate/Timolol120$53,396
VyzultaLatanoprostene Bunod102$44,545
Brimonidine Tartrate529$40,342
TafluprostTafluprost/Pf150$36,974
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol154$31,349
Dorzolamide-TimololDorzolamide/Timolol/Pf121$29,435
Cyclosporine34$23,908
Travoprost76$18,595
BesivanceBesifloxacin Hcl78$17,435
Latanoprost1,186$15,718
ProlensaBromfenac Sodium41$14,363

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Alphagan P, Combigan$203$596,270957 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$38$103,141181 claims
Bausch & Lomb Americas Inc.Vyzulta$93$44,545102 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCBesivance, Prolensa, Lotemax Sm$106$35,783135 claims
AlconSimbrinza$418$6,23825 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in Bradenton

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →